23-089
Zeinab Hosseinidoust Tohid Didar Fereshteh Bayat
PCT Filed
Pilot stage
Amy Hector Business Development Manager
Bacteriophages continue to gain regulatory approval for human therapeutic use, as well as antimicrobial use in food and agricultural settings against antibiotic-resistant bacteria, resulting in a clear need for rapid susceptibility profiling of bacterial isolates against large, decentralized phage biobanks. The current gold standard in phage susceptibility testing, which has remined unchanged for over a century, is the culture method, which can take from overnight to several days. The challenge is compounded by the lack of a global phage biobank, a reality that may persist for the foreseeable future, making phage antimicrobial use reliant on decentralized phage biobanks around the world.
Researchers at McMaster have developed a high throughput, point-of-use platform technology that allows for packaging and stabilization of bacteriophage biobanks along with the detection biochemistry, enabling rapid (as fast as 30 min) susceptibility profiling for a bacterial isolate of interest in a one-pot format.